中国P站

Atherosclerosis, a progressive disease characterized by the accumulation of lipid-rich plaques within the arterial walls, remains a leading cause of cardiovascular morbidity and mortality worldwide. Despite decades of research, its complex pathophysiology continues to be an area of intense scientific investigation. Traditionally, the disease has been viewed primarily as a disorder of cholesterol metabolism; however, emerging evidence underscores its inflammatory, genetic, and immune-mediated components, prompting a shift in therapeutic and diagnostic approaches. The interplay between endothelial dysfunction, lipid deposition, oxidative stress, and immune activation makes atherosclerosis a multifaceted condition requiring innovative solutions beyond conventional lipid-lowering therapies [1].

Recent advancements in molecular biology, genomics, and biomedical engineering have catalyzed breakthroughs in atherosclerosis research, paving the way for more precise diagnostic tools and targeted interventions. Investigations into plaque composition, mechanotransduction, and endothelial cell biology have revealed key insights into disease progression, allowing researchers to develop novel pharmacological agents and regenerative therapies. Moreover, the integration of artificial intelligence and machine learning in cardiovascular medicine is refining risk assessment and predictive modeling, enabling earlier and more accurate identification of high-risk individuals. With the emergence of gene-editing technologies, stem cell therapies, and nanomedicine, the future of atherosclerosis research appears promising, potentially revolutionizing treatment paradigms and reducing the global burden of cardiovascular disease [2].

Description

One of the most significant advances in atherosclerosis research is the growing recognition of inflammation as a central driver of disease progression. Studies have demonstrated that the inflammatory cascade triggered by endothelial injury contributes to plaque instability, increasing the risk of acute cardiovascular events. This has led to the development of targeted anti-inflammatory therapies, such as interleukin-1 beta inhibitors, which have shown promising results in reducing cardiovascular events in clinical trials. Monoclonal antibodies against pro-inflammatory cytokines and immune modulators aimed at dampening chronic vascular inflammation represent a new frontier in atherosclerosis management [3].

In addition to inflammation, lipid metabolism continues to be a crucial focus of research, with novel lipid-lowering agents emerging beyond statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C), offering an alternative for statin-intolerant patients. Small interfering RNA (siRNA) therapies targeting cholesterol metabolism genes, such as ANGPTL3, are further refining lipid regulation strategies. Meanwhile, high-density lipoprotein (HDL) therapeutics aimed at reverse cholesterol transport are under investigation, providing potential avenues for plaque regression and cardiovascular protection [4].

Technological innovations have also transformed diagnostic approaches, with advanced imaging techniques improving the detection and characterization of atherosclerotic plaques. High-resolution magnetic resonance imaging (MRI), positron emission tomography (PET), and intravascular ultrasound (IVUS) enable precise assessment of plaque vulnerability, facilitating personalized risk stratification. The integration of artificial intelligence in cardiovascular imaging allows for real-time analysis of vascular health, enabling early identification of subclinical atherosclerosis [5]. Machine learning algorithms trained on large-scale datasets are refining predictive models, allowing clinicians to anticipate disease progression with unprecedented accuracy.

Regenerative medicine and gene therapy are reshaping therapeutic strategies for atherosclerosis, offering potential for vascular repair and disease modification. Stem cell-based interventions, including endothelial progenitor cells and mesenchymal stem cell therapies, aim to restore endothelial function and reverse plaque formation. Exosome-based approaches harness the regenerative capabilities of extracellular vesicles to modulate vascular inflammation and improve endothelial repair. Additionally, gene-editing technologies such as CRISPR/Cas9 hold promise for correcting genetic predispositions to atherosclerosis, enabling precise modification of disease-associated genes to prevent progression [6].

Nanotechnology has emerged as a powerful tool in atherosclerosis treatment, with nanocarriers and nanoparticles facilitating targeted drug delivery to atherosclerotic plaques [7]. Nano-formulated antioxidants and anti-inflammatory agents are designed to reduce oxidative stress and suppress immune activation at the site of endothelial injury. Lipid nanoparticles used in mRNA therapeutics have opened new avenues for cardiovascular medicine, with ongoing research exploring their potential in gene-based interventions for atherosclerosis [8].

Conclusion

Atherosclerosis research has entered a transformative era, with advancements in molecular biology, immunology, regenerative medicine, and artificial intelligence reshaping our understanding of the disease. The recognition of inflammation as a key player in disease progression has driven the development of targeted anti-inflammatory therapies, while innovations in lipid-lowering strategies provide new avenues for preventing plaque formation. The integration of cutting-edge imaging modalities and artificial intelligence in cardiovascular diagnostics enables earlier detection and personalized risk assessment, improving clinical outcomes. Looking ahead, future research must focus on optimizing the safety and efficacy of regenerative medicine and gene-editing approaches to ensure their clinical translation. The promise of nanotechnology in targeted drug delivery holds immense potential for minimizing systemic side effects and enhancing therapeutic precision. As interdisciplinary collaborations continue to drive innovation, the field of atherosclerosis research is poised to make groundbreaking strides in treatment and prevention, offering hope for reducing the global burden of cardiovascular disease. By leveraging these advancements, the medical community can develop more effective and personalized strategies, improving the lives of millions affected by atherosclerosis.

Acknowledgement

None

Conflict of Interest

None

References

1. Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW, et al. (2004) Circulation 109: 2993-2999.

   , ,

2. Lin FY, Shaw LJ, Dunning AM, LaBounty TM, Choi JH, et al. (2011) J Am Coll Cardiol 58: 510-519.

   , ,

3. Lichtlen PR, Bargheer K, Wenzlaff P (1995) J Am Coll Cardiol 25: 1013-1018.

   , ,

4. Elgendy IY, Pepine CJ (2019) . Am J Med 132: 692-697.

   , ,

5. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, et al. (2017) N Engl J Med 377: 1119-1131.

   , ,

6. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, et al. (2019) N Engl J Med 381: 2497-2505.

   , ,

7. Sagris M, Antonopoulos AS, Theofilis P, Oikonomou E, Siasos G (2022) Cardiovasc Res 118: 2281-2292.

   , ,

8. Zanatta E, Colombo C, D’Amico G, d’Humieres T, Dal Lin C, et al. (2019) Int J Mol Sci 20: 5563.

   , ,